Conclusions: Functional activation of Gα q proteins coupled to dopamine D 1 -like receptor and α 1 -adrenoceptor is detectable by means of [ 35 S]GTPγS binding/immunoprecipitation assay in rat brain membranes. Several compounds exhibit curious behaviors in this assay system, for which further investigations are necessary.
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Upregulation of zinc transporter, solute carrier family 39, member 12, in the cortex of subjects with schizophrenia 
Abstract
Zinc is an important trace element essential for normal brain functioning, and thus requires tight regulation. Using an expression microarray we showed that mRNA for a zinc transporter, solute carrier family 39, member 12 (SLC39A12), was higher in the dorsolateral pre-frontal cortex of subjects with schizophrenia compared to control 1 . The aims of this study were to validate this finding using quantitative PCR (qPCR), measure the extent of this upregulation across the cortex, determine if changes show disease specificity or could be due to a mechanism of action of antipsychotic drugs, and confirm that this previously uncharacterised protein could transport zinc across the cell membrane.
qPCR was used to measure mRNA levels for the two known human SLC39A12 variants, 1 and 2, in Brodmann's areas (BA) 8, 9 and 44 from 30 subjects with schizophrenia and 30 age/sex matched control, as well as in BA 9 from 10 subjects with bipolar disorder (BPD), 10 with major depressive disorder (MDD) and 9 matched control. Slc39a12 mRNA was also measured in the cortex of rats treated with haloperidol, chlorpromazine or thioridazine for 12 months.
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Zinc uptake was measured in Chinese hamster ovary (CHO) cells overexpressing SLC39A12 variant 1 or 2.
Levels of SLC39A12 variant 1 mRNA was higher in BA 8 and 44 from subjects with schizophrenia compared to control, while variant 2 was higher in schizophrenia in all cortical regions examined. There were no differences in levels of SLC39A12 mRNA in BA 9 from subjects with BPD or MDD, or in the rat cortex after treatment with antipsychotic drugs.
Zinc uptake was increased in cells overexpressing either SLC39A12 variant 1 or 2.
These findings suggest an upregulation of SLC39A12 in the cortex of people with schizophrenia, with a possible disruption in cortical zinc homeostasis contributing to the pathophysiology of the disorder. 
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The (Cleva and Olive, 2011) . Recent evidence suggests that allosteric modulators have adverse pharmacological effects when bound to the monomeric, compared to the dimeric form of these receptors (El Moustaine et al., 2012) . Investigating the neurodevelopmental expression of dimeric and monomeric mGluR1 and mGluR5 may highlight possible implications for novel therapeutics at critical neurodevelopmental periods. Methods: Pregnant Sprague-Dawley rats were obtained at gestational day 14. Offspring were euthanised on postnatal day (PN) 12, 35 and 96 (n=6/group) coinciding with juvenile, adolescent and adult time points. Immunoblots were performed on prefrontal cortex (PFC) and hippocampal tissue under non-reducing conditions to measure dimeric and monomeric mGluR1 and mGluR5 proteins. Results: Dimeric mGluR1and mGluR5 was expressed in higher abundance than their monomeric forms. mGluR1 dimeric expression was lowest at PN12 in both the PFC and hippocampus; where it displayed an increase with age. Whilst monomeric mGluR1 expression was considerably lower, it showed a similar trend in the PFC, however, its expression remained constant in the hippocampus. In contrast, dimeric mGluR5 protein expression in the PFC peaked at PN12 and decreased throughout the neurodevelopmental time-points, however its expression in the hippocampus remained constant throughout. Interestingly, in both regions mGluR5 monomer was highly expressed at PN12, almost equal to dimeric expression and then declined to the lowest limits of detection at later time-points. Conclusion: The monomeric form of mGluR5 is relatively abundant during early post-natal development. Considering positive allosteric modulators exert an unregulated agonist effect when bound to the monomeric form of mGluRs, administration of these compounds during such a critical neurodevelopmental period, may cause seizures and neurotoxic effects, posing possible consequences for novel mGluR5 therapeutics.
